Tirzepatide

A sealed lyophilized vial is stored at -20 °C, protected from light and moisture: in that state the dry powder is stable for months to years. That differs from storing the already reconstituted solution (2–8 °C, a few weeks). See the full storage and lab-handling breakdown on the documentation page /en/docs/tirzepatide.

Tirzepatide comes in three package sizes: 5 mg, 30 mg, and 120 mg. Pick the one you need in the size selector above.

The reconstituted solution should be stored at 2–8 °C. Detailed storage conditions and shelf-life after reconstitution are provided on the label and in the LOT technical documentation.

No. Tirzepatide from Longeva is a research molecule, not a brand name. It is neither Mounjaro (a pharmaceutical drug) nor Zepbound (a brand name), but a pure research sample for laboratory purposes.

RUO means the product is intended exclusively for scientific research in laboratory settings. Tirzepatide from Longeva is not a medicine and is not permitted for clinical use or human application.

Tirzepatide is supplied as a lyophilized powder, which ensures molecular stability during storage and ease of reconstitution for research applications.

Batches of Tirzepatide are tested by independent third-party laboratories, and we publish the reports in the open COA archive. Check the current list of reports for this substance at /coa?q=tirzepatide to see which batches already have a published certificate.

Tirzepatide is a research molecule, a synthetic dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. For a full breakdown of the receptors, mechanism, and weekly profile, see the wiki reference: /wiki/tirzepatide.

The half-life of tirzepatide is approximately 5 days. The figure is stated in both the FDA and EMA labels; a population pharmacokinetic analysis across 5,802 participants gives a half-life of 5.4 days. See the Dosing section for detail.